Basic research in HIV vaccinology is hampered by reductionist thinking

Frontiers in Immunology

Volumn 3, Issue JUL, 2012, Pages

  Van Regenmortel, Marc H V ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Antibody affinity maturation; Antibody polyspecificity; Discontinuous protein epitopes; Hiv vaccines; Rational vaccine design; Reductionism; Reverse vaccinology; Systems biology

Indexed keywords

EID: 84871403286     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00194     Document Type: Article

References (245)

1. A systems approach to dissecting immunity and inflammation. Semin. Immunol. 16,55-67.
2. Agarwal, A., Hioe, C. E., Swet-nam, J., Zolla-Pazner, S., and Cardozo, T. (2011). Quantitative assessment of masking of neutraliza-tion epitopes in HIV-1. Vaccine 29, 6736-6741.
3. Alam, S. M., Morelli, M., Denni-son, S. M., Liao, H. X., Zhang, R., Xia, S. M., Rits-Volloch, S., Sun, L., Harrison, S. C., Haynes, B. F., and Chen, B. (2009). Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. U.S.A. 106, 20234-20239.
4. Allen, J. F. (2001). Bioinformatics and discovery: induction beckons again. Bioessays 23, 104-107.
5. Al Moudallal, Z., Briand, J. P., and Van Regenmortel, M. H. V. (1982). Mon-oclonal antibodies as probes of the antigenic structure of tobaccomosaic virus. EMBO J. 1, 1005-1010.
6. Amzel, L. M. (1998). Structure-based drug design. Curr. Opin. Biotechnol. 9,366-369.
7. Andris, J. S., Johnson, S., Zolla-Pazner, S., and Capra, J. D. (1991). Molec-ular characterization of five human anti-human immunodeficiency virus type 1 antibody heavy chains reveals extensive somatic mutation typical of an antigen-driven immune response. Proc. Natl. Acad. Sci. U.S.A. 88, 7783-7787.
8. Arnaout, R., Lee, W., Cahill, P., Honan, T., Sparrow, T., Weiand, M., Nus-baum, C., Rajewsky, K., and Koralov, S.B. (2011).High-resolutiondescrip-tion of antibody heavy-chain reper-toires in humans. PLoS ONE 6, e22365. doi: 10.1371/jour-nal.pone.0022365
9. Arnold, G. F., Velasco, P. K., Holmes, A. K., Wrin, T., Geisler, S. C., Phung, P., Tian, Y., Resnick, D. A., Ma, X., Mariano, T. M., Petropoulos, C. J., Taylor, J. W., Katinger, H., and Arnold, E. (2009). Broad neutral-ization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J. Virol. 83,5087-50100.
10. Azoitei, M. L., Correia, B. E., Ban, Y. E., Carrico, C., Kalyuzhniy, O., Chen, L., Schroeter, A., Huang, P. S., McLellan, J. S., Kwong, P. D., Baker, D., Strong, R. K., and Schief, W. R. (2011). Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science 334,373-376.
11. Berger, R. (1998). Understanding sci-ence: why causes are not enough. Philos. Sci. 65,306-332.
12. Bhattacharjee, A. K., and Glaude-mans, C. P. (1978). Dual binding specificities in MOPC 384 and 870 murine myeloma immunoglobulins. J. Immunol. 120,411-413.
13. Blalok, J. (1990). Complementarity of peptides specified by "sense" and "antisense" strands of DNA. Trends Biotechnol. 8, 140-144.
14. Bock,G.,andGoode,J.(1998).The Lim-its of Reductionism in Biology. Novar-tis Foundation Symposium No. 213. Chichester: Wiley.
15. Bosshard, H. R. (2001). Molecular recognition by induced fit: how fit is the concept? News Physiol. Sci. 16, 171-173.
16. Bradie, M. (2003). Review of What Genes Can't Do by Lenny Moss. A BradfordBook.TheMITPress,Cam-bridge, MA. Hum. Nat. Rev.3, 317-320.
17. Bramwell, V. W., and Perrie, Y. (2005). The rational design of vaccines. Drug Discov. Today 10, 1527-1534.
18. Brenner, S. (2010). Sequences and con-sequences.Philos.Trans.R.Soc.Lond. B Biol. Sci. 365, 207-212.
19. Broder, C. C., Earl, P. L., Long, D., Abedon, S. T., Moss, B., and Doms, R. W. (1994). Antigenic implications of human immunodeficiency virus type 1 envelope quaternary struc-ture: oligomer-specific and -sensitive monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 91, 11699-11703.
20. Bunge, M. (2003). Philosophical Dic-tionary. Amherst, NY: Prometheus Books.
21. Burke,V.,Williams,C.,Sukumaran,M., Kim,S.S.,Li,H.,Wang,X.H.,Gorny, M. K., Zolla-Pazner, S., and Kong, X. P. (2009). Structural basis of the cross-reactivity of genetically related human anti-HIV-1 monoclonal anti-bodies: implications for design of V3-based immunogens. Structure 17, 1538-1546.
22. Burton, D. R. (2002). Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2,706-713.
23. Burton, D. R. (2010). Scaffolding to build a rational vaccine design strat-egy. Proc. Natl. Acad. Sci. U.S.A. 107, 17859-17860.
24. Burton, D. R., Pyati, J., Koduri, R., Sharp, S. J., Thornton, G. B., Par-ren, P. W., Sawyer, L. S., Hendry, R. M., Dunlop, N., Nara, P. L., Lamac-chia, M., Garratty, E., Stiehm, E. R., Bryson,Y. J.,Cao,Y.,Moore,J. P.,Ho, D. D., and Barbas, III, C.F. (1994). Efficient neutralization of primary isolates of HIV-1 by a recombinant humanmonoclonalantibody.Science 266,1024-1027.
25. Burton, D. R., Stanfield, R. L., and Wilson, I. A. (2005). Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. U.S.A. 102, 14943-14948.
26. Byerly,H. (2003). Reductionism: analy-sis and synthesis in biological expla-nations. Q. Rev. Biol. 78,336-342.
27. Cartwright, N. (1983). How the Laws of Physics Lie. Oxford: Oxford Univer-sity Press.
28. Changela, A., Wu, X., Yang, Y., Zhang, B., Zhu, J., Nardone, G. A., O'Dell, S., Pancera, M., Gorny, M. K., Phogat, S., Robinson, J. E., Sta-matatos,L.,Zolla-Pazner,S.,Mascola, J. R., and Kwong, P. D. (2011). Crys-talstructureof humanantibody2909 reveals conserved features of qua-ternary structure-specific antibodies that potently neutralize HIV-1. J. Virol. 85,2524-2535.
29. Chatellier, J., Van Regenmortel, M. H. V., Vernet, T., and Altschuh, D. (1996). Functional mapping of con-served residues located at theVL and VH domain interface of a Fab. J. Mol. Biol. 264, 1-6.
30. Chen,S.W.,VanRegenmortel,M.H.V., andPellequer,J.-L.(2009).Structure-activity relationships in peptide-antibody complexes: implications for epitope prediction and development of synthetic peptide vaccines. Curr. Med. Chem. 16,953-964.
31. Chen, W., Streaker, E. D., Russ, D. E., Feng, Y., Prabakaran, P., and Dimitrov, D. (2012). Characteriza-tion of germline antibody libraries from human umbilical cord blood and selection of monoclonal anti-bodies to viral envelope glycopro-teins:implicationsformechanismsof immune evasion and design of vac-cine immunogens. Biochem. Biophys. Res. Commun. 417,1164-1169.
32. Cho,M.W.,Lee,M.K.,Chen,C. H., Matthews, T., and Martin, M. A. (2000). Identification ofgp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate. J. Virol. 74, 9749-9754.
33. Cohen, J., and Stewart, L. (1994). The Collapse of Chaos.NewYork:Pen-guins Books.
34. Cornish-Bowden,A.(2006).Puttingthe systems back into systems biology. Perspect. Biol. Med. 49, 475-489.
35. Cornish-Bowden, A. (2011). Systems biology. How far has it come? Bio-chemist 33, 16-18.
36. Correia, B. E., Ban, Y. E., Holmes, M. A., Xu, H., Ellingson, K., Kraft, Z., Carrico, C., Boni, E., Sather, D. N., Zenobia, C., Burke, K. Y., Bradley-Hewitt, T., Bruhn-Johannsen, J. F., Kalyuzhniy, O., Baker, D., Strong, R. K., Stamatatos, L., and Schief, W. R. (2010). Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 18,1116-1126.
37. Corti, D., Langedijk, J. P., Hinz, A., Seaman, M. S., Vanzetta, F., Fernandez-Rodriguez, B. M., Silacci, C., Pinna, D., Jarrossay, D., Balla-Jhagjhoorsingh, S., Willems, B., Zekveld, M. J., Dreja, H., O'Sullivan, E., Pade, C., Orkin, C., Jeffs, S. A., Montefiori, D. C., Davis, D., Weis-senhorn, W., McKnight, A., Heeney, J. L., Sallusto, F., Sattentau, Q. J., Weiss, R. A., and Lanzavecchia, A. (2010). Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutral-izing breadth from HIV-1-infected individuals. PLoS ONE 5, e8805. doi: 10.1371/journal.pone.0008805
38. Crick,F. H. C. (1966). Of Molecules and Men. Seattle: University of Washing-ton Press.
39. Cunningham, B. C., and Wells, J. A. (1993). Comparison of a structural and a functional epitope. J. Mol. Biol. 234,554-563.
40. D'Argenio, D. A., and Wilson, C. B. (2010). A decade of vaccines: inte-gratingimmunologyandvaccinology forrationalvaccinedesign.Immunity 33, 437-440.
41. Day, E. D. (1990). Advanced Immuno-chemistry, 2nd Edn. New York: John Wiley and Sons.
42. De Clercq, E. (2009). The history of antiretrovirals: key discoveries over the past 25 years. Rev. Med. Virol. 19, 287-299.
43. Denisova, G. F., Denisov, D. A., and Bramson, J. L. (2010). Apply-ing bioinformatics for antibody epitope prediction using affinity-selected mimotopes -relevance for vaccine design. Immunome Res. 6(Suppl. 2),S6.
44. Dey, B., Pancera, M., Svehla, K., Shu, Y., Xiang, S. H., Vainshtein, J., Li, Y., Sodroski, J., Kwong, P. D., Mas-cola, J. R., and Wyatt, R. (2007). Characterization of human immun-odeficiency virus type 1 monomeric andtrimericgp120glycoproteinssta-bilized in the CD4-bound state: anti-genicity, biophysics, and immuno-genicity. J. Virol. 81,5579-5593.
45. Dey, B., Svehla, K., Xu, L., Wycuff, D., Zhou, T., Voss, G., Phogat, A., Chakrabarti, B. K., Li, Y., Shaw, G., Kwong, P. D., Nabel, G. J., Mascola, J. R., and Wyatt R. T. (2009). Structure-based sta-bilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog. 5, e1000445. doi: 10.1371/journal.ppat.1000445
46. Dimitrov, D. S. (2010). Therapeutic antibodies, vaccines and antibody-omes. MAbs 2,347-356.
47. Doria-Rose, N. A., Louder, M. K.,Yang, Z., O'Dell, S., Nason, M., Schmidt, S. D., McKee, K., Seaman, M. S., Bailer, R. T.,and Mascola,J. R. (2012). HIV-1neutralizationcoverageisimproved by combining monoclonal antibod-ies that target independent epitopes. J. Virol. 86,3393-3397.
48. Douek, D. C., Kwong, P. D., and Nabel, G. J. (2006). The rational design of an AIDS vaccine. Cell 124, 677-681.
49. Du, S. X., Idiart, R. J., Mariano, E. B., Chen, H., Jiang, P., Xu, L., Ostrow, K. M., Wrin, T., Phung, P., Binley, J. M., Petropoulos, C. J., Ballantyne, J. A., and Whalen, R. G. (2009). Effect of trimerization motifs on qua-ternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein. Virology 395,33-44.
50. Dupré,J.(1993).TheDisorderofThings. Metaphysical Foundations of the Dis-unity of Science. Cambridge, MA: Harvard University Press.
51. Edwards, B. M., Barash, S. C., Main, S. H., Choi, G. H., Minter, R., Ull-rich, S., Williams, E., Du Fou, L., Wilton, J., Albert, V. R., Ruben, S. M., and Vaughan, T. J. (2003). The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. J. Mol. Biol. 334, 103-118.
52. Eisen, H. N., and Chakraborty, A. K. (2010). Evolving concepts of speci-ficity in immune reactions. Proc. Natl. Acad. Sci. U.S.A. 107, 22373-22380.
53. Euler, Z., van den Kerkhof, T. L., van Gils, M. J., Burger, J. A., Edo-Matas, D., Phung, P., Wrin, T., and Schuitemaker, H. (2012). Longitudi-nal analysis of early HIV-1-specific neutralizing activity in an elite neu-tralizer and in five patients who developed cross-reactive neutralizing activity. J. Virol. 86,2045-2055.
54. Fischer, N. (2011). Sequencing anti-bodyrepertoires,thenextgeneration. MAbs 3, 17-20.
55. Frank, S. A. (2002). Immunology and Evolution of Infectious Dis-ease. Princeton: Princeton University Press.
56. Gannon, F. (2007). Too complex to comprehend? EMBO Rep. 8,705.
57. Gatherer, D. (2010). So what do we really mean when we say that systems biology is holistic? BMC Syst. Biol. 4, 22. doi: 10.1186/1752-0509-4-22
58. Getzoff, E. D., Tainer, J. A., Lerner, R. A., and Geysen, H. M. (1988). The chemistry and mechanism of anti-body binding to protein antigens. Adv. Immunol. 43,1-98.
59. Geysen,H. M.,Mason,T. J.,and Rodda, S. J. (1988). Cognitive features of continuous antigenic determinants. J. Mol. Recognit. 1,32-41.
60. Giere, R. N. (1988). Explaining Science. Chicago:Universityof ChicagoPress. Gigerenzer, G., and Selten, R. (2001). "Rethinking rationality," in Bounded Rationality: The Adaptive Tool-box, eds G. Gigerenzer, and R. Selten (Cambridge: MIT Press), 147-171.
61. Gigerenzer,G.,andSelten,R.(2001). "Rethinking rationality," in Bounded Rationality: The Adaptive Tool- box, eds G. Gigerenzer, and R. Selten (Cambridge: MIT Press), 147-171
62. Gorny, M. K., Stamatatos, L.,Volsky, B., Revesz,K.,Williams,C.,Wang,X. H., Cohen, S., Staudinger, R., and Zolla-Pazner, S. (2005). Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J. Virol. 79, 5232-5237.
63. + T cell decline and high viral load during acute infection. J. Virol. 85, 4828-4840.
64. Gray, E. S., Moore, P. L., Bibollet-Ruche, F., Li, H., Decker, J. M., Meyers, T., Shaw, G. M., and Mor-ris, L. (2008). 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individ-ualwithananti-membrane-proximal external region-neutralizing anti-body response. J. Virol. 82, 2367-2375.
65. Greenspan, N. S., and Di Cera, E. (1999). Defining epitopes: It's not as easy as it seems. Nat. Biotechnol. 17, 936-937.
66. Greek, R. (2012). Animal models and the development of an HIV vaccine. J. AIDS Clin. Res. S8,001.
67. Guenaga, J., Dosenovic, P., Ofek, G., Baker, D., Schief, W. R., Kwong, P. D., Karlsson Hedestam, G. B., and Wyatt, R. T. (2011). Heterolo-gous epitope-scaffold prime: boost-ing immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutral-ization determinant. PLoS ONE 6, e16074. doi: 10.1371/journal.pone. 0016074
68. Feytmans,E.,Noble,D.,andPeitsch,M. (2005). Genome size and numbers of biological functions. Trans. Comput. Syst. Biol. 1,44-49.
69. Hacking, I. (1983). Representing and Intervening. Cambridge, UK: Cam-bridge University Press.
70. Hanin, V., Déry, O., Boquet, D., Sagot, M. A., Créminon, C., Couraud, J. Y., and Grassi, J. (1997). Importance of hydro-pathic complementarity for the binding of the neuropeptide sub-stance P to a monoclonal antibody: equilibrium and kinetic studies. Mol. Immunol. 34, 829-838
71. Hanke, D. (2004). "Teleology: the explanation that bedevils biology,"in Explanations: Styles of Explanation in Science, ed. J. Cornwell (Oxford: Oxford University Press),143-155.
72. Hans, D., Young, P. R., and Fairlie, D. P. (2006). Current status of short synthetic peptides as vaccines. Med. Chem. 2,627-646.
73. Harris,A.,Borgnia,M. J.,Shi,D.,Barte-saghi, A., He, H., Pejchal, R., Kang, Y. K., Depetris, R., Marozsan, A. J., Sanders, R. W., Klasse, P. J., Milne, J. L.,Wilson,I.A.,Olson,W.C.,Moore, J. P., and Subramaniam, S. (2011). Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 enve-lope glycoproteins display the same closed and open quaternary molecu-lar architectures. Proc Natl. Acad. Sci. U.S.A. 108,11440-11445.
74. Haynes, B. F., Fleming, J., St Clair, E. W., Katinger, H., Stiegler, G., Kunert, R., Robinson, J., Scearce, R. M., Plonk, K., Staats, H. F., Ortel, T. L., Liao, H. X., and Alam, S. M. (2005a). Cardiolipin polyspecific autoreactivityintwobroadlyneutral-izing HIV-1 antibodies. Science 308, 1906-1908.
75. Haynes, B. F., Moody, M. A., Verkoczy, L., Kelsoe, G., and Alam, S. M. (2005b). Antibody polyspeci-ficity and neutralization of HIV-1: a hypothesis. Hum. Antibodies 14, 59-67.
76. Hilleman, M. R. (1992). Impediments, imponderablesandalternativesinthe attempt to develop an effective vac-cine against AIDS. Vaccine 10, 1053-1058.
77. Ho, J., Uger, R. A., Zwick, M. B., Luscher, M. A., Barber, B. H., and MacDonald,K.S.(2005).Conforma-tional constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but notneutralizingresponse.Vaccine 23, 1559-1573.
78. Hofnung, M., and Charbit, A. (1993). "Expression of antigens as recom-binant proteins," in Structure of Antigens, Vol. 2, ed. M. H. V. Van Regenmortel (Boca Raton, FL: CRC Press), 79-128.
79. Holland,J. H. (1994). Emergence. Read-ing,UK: Perseus Books.
80. Honnen, W. J., Krachmarov, C., Kay-man, S. C., Gorny, M. K., Zolla-Pazner, S., and Pinter, A. (2007). Type-specific epitopes targeted by monoclonal antibodies with excep-tionally potent neutralizing activities forselectedstrainsofhumanimmun-odeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence. J. Virol. 81,1424-1432.
81. Huang, C. C., Venturi, M., Majeed, S., Moore,M.J.,Phogat,S.,Zhang,M.Y., Dimitrov, D. S., Hendrickson, W. A., Robinson, J., Sodroski, J., Wyatt, R., Choe, H., Farzan, M., and Kwong, P. D.(2004).Structuralbasisof tyrosine sulfation and VH-gene usage in anti-bodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc. Natl. Acad. Sci. U.S.A. 101, 2706-2711.
82. Huang, C. C., Tang, M., Zhang, M. Y., Majeed, S., Montabana, E., Stanfield, R. L., Dimitrov, D. S., Korber, B., Sodroski, J., Wilson, I. A., Wyatt, R., andKwong,P.D.(2005). Structureof a V3-containing HIV-1 gp120 core. Science 310,1025-1028.
83. Ideker, T., Galitski, T., and Hood, L. (2001). A new approach to decod-ing life: systems biology. Annu. Rev. Genomics Hum. Genet. 2, 243-272.
84. Irving, M. B., Pan, O., and Scott, J. K. (2001). Random-peptide libraries and antigen-fragment libraries for epitope mapping and the develop-ment of vaccines and diagnostics. Curr. Opin. Chem. Biol. 5, 314-324.
85. Irving, M. B., Craig, L., Menendez, A., Gangadhar, B. P., Montero, M., van Houten, N. E., and Scott, J. K. (2010). Exploringpeptidemimicsfor the production of antibodies against discontinuous protein epitopes. Mol. Immunol. 47, 1137-1148.
86. James, L. C., Roversi, P., and Tawfik, D. S. (2003). Antibody multi-specificity mediated by conformational diver-sity. Science 299, 1362-1367.
87. Javaherian,K.,Langlois,A. J.,McDanal, C., Ross, K. L., Eckler, L. I., Jellis, C. L., Profy, A. T., Rusche, J. R., Bolog-nesi, D. P., and Putney, S. D. (1989). Principal neutralizing domain of the human immunodeficiency virus type 1envelopeprotein.Proc. Natl. Acad. Sci. U.S.A. 86,6768-6772.
88. Joyce, J. G., Hurni, W. M., Bogusky, M. J., Garsky, V. M., Liang, X., Citron, M. P.,Danzeisen,R. C.,Miller,M. D., Shiver,J. W.,and Keller,P. M. (2002). Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. J. Biol. Chem. 277, 45811-45820.
89. Julien, J. P., Bryson, S., Nieva, J. L., and Pai, E. F. (2008). Struc-tural details of HIV-1 recognition by the broadly neutralizing mono-clonal antibody 2F5: epitope con-formation, antigen-recognition loop mobility, and anion-binding site. J. Mol. Biol. 384,377-392.
90. Karlsson-Hedestam, G. B., Fouchier, R. A., Phogat, S., Burton, D. R., Sodroski, J., and Wyatt, R. T. (2008). The challenges of eliciting neutral-izing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol. 6, 143-155.
91. Kay, L. E. (2000). Who Wrote the Book of Life: A History of the Genetic Code. Stanford: Stanford University Press. Kell, D. B., and Oliver, S. G. (2004). Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis-driven science in the post-genomic era. Bioessays 26,99-105.
92. Kelley, L., and Scott, M. (2008). The evolution of biology. EMBO Rep.9, 1163-1167.
93. Khan, T., and Salunke, D. M. (2012). Structural elucidation of the mecha-nistic basis of degeneracy in the pri-mary humoral response. J. Immunol. 188,1819-1827.
94. Kim, M., Sun, Z. Y., Rand, K. D., Shi, X., Song, L., Cheng, Y., Fahmy, A. F., Majumdar, S., Ofek, G., Yang, Y., Kwong, P. D., Wang, J. H., Engen, J. R., Wagner, G., and Reinherz, E. L. (2011). Antibody mechanics onamembrane-boundHIVsegment essentialforGP41-targetedviralneu-tralization. Nat. Struct. Mol. Biol. 18, 1235-1243.
95. Kimura, T., Wang, X. H., Williams, C., Zolla-Pazner, S., and Gorny, M. K. (2009). Human monoclonal antibody 2909 binds to pseudoviri-ons expressing trimers but not monomericHIV-1envelopeproteins. Hum. Antibodies 18,35-40.
96. Kistler, M. (2003). Available at: http://www.institutnicod.org/ reduction.htm
97. Kitano, H. (2002). Systems biology: a brief overview. Science 295, 1662-1664.
98. Klee, R. (1997). Introduction to the Phi-losophy of Science. Cutting Nature at its Seams. New York: Oxford Univer-sity Press.
99. Kong, L., and Sattentau, Q. J. (2012). Antigenicity and immunogenicity in HIV-1 antibody-based vaccine design. J. AIDS Clin. Res. S8,003.
100. Koup, R. A., Graham, B. S., and Douek, D. C. (2011). The quest for a T cell-basedimmunecorrelateofprotection against HIV: a story of trials and errors. Nat. Rev. Immunol. 11,65-70.
101. Krachmarov, C., Pinter,A., Honnen,W. J.,Gorny,M.K.,Nyambi,P.N.,Zolla-Pazner, S., and Kayman, S. C. (2005). Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade A and clade B V3domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epi-tope masking. J. Virol. 79,780-790.
102. Kumar, R., Visciano, M. L., Li, H., and Hioe, C. (2012). Targeting a neutral-izing epitope of HIV envelope gp120 by immune complex vaccine. J. AIDS Clin. Res. S8,002.
103. Kuntz, I. D. (1992). Structure-based strategies for drug design and discov-ery. Science 257,1078-1082.
104. Kusters, I., and Almond, J. W. (2010). "Vaccine strategies," in Desk Encyclo-pedia of General Virology,edsB.W.J. Mahy and M. H. V. Van Regenmortel (Oxford: Academic Press, Elsevier), 381-389.
105. Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., and Hen-drickson, W. A. (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393,648-659.
106. Laal, S., Burda, S., Gorny, M. K., Kar-wowska, S., Buchbinder, A., and Zolla-Pazner, S. (1994). Synergistic neutralizationof humanimmunode-ficiency virus type 1 by combinations of human monoclonal antibodies. J. Virol. 68,4001-4008.
107. Labrijn, A. F., Poignard, P., Raja, A., Zwick,M. B.,Delgado,K.,Franti,M., Binley, J., Vivona, V., Grundner, C., Huang, C. C.,Venturi, M., Petropou-los, C. J., Wrin, T., Dimitrov, D. S., Robinson, J., Kwong, P. D., Wyatt, R. T., Sodroski, J., and Burton, D. R. (2003). Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is steri-cally restricted on primary human immunodeficiency virus type 1. J. Virol. 77,10557-10565.
108. LaFemina, R. L. (2009). Antiviral Research Strategies in Antiviral Drug Discovery. Washington, DC: ASM Press.
109. Laland, K. N., Sterelny, K., Odling-Smee, J., Hoppitt, W., and Uller, T. (2011). Cause and effect in biology revisited: Mayr's proximate-ultimate dichotomy still useful? Science 334, 1512-1516.
110. Law, M., Cardoso, R. M., Wil-son, I. A., and Burton, D. R. (2007). Antigenic and immunogenic study of membrane-proximal exter-nal region-grafted gp120 antigens by a DNA prime-protein boost immu-nization strategy. J. Virol. 81, 4272-4285.
111. Lescar, J., Pelligrini, M., Souchon, H., Tello, D., Poljak, R. J., Peterson, N., Greene, M., and Alzari, M. (1995). Crystal structure of a crossreaction-complex between Fab F9.13.7 and guinea fowl lysozyme. J. Biol. Chem. 270,18067-18076.
112. Li, Y., Migueles, S. A., Welcher, B., Svehla, K., Phogat, A., Louder, M. K., Wu, X., Shaw, G. M., Connors, M., Wyatt, R. T., and Mascola, J. R. (2007). Broad HIV-1 neutraliza-tion mediated by CD4-binding site antibodies. Nat. Med. 13,1032-1034.
113. Liao, H. X., Chen, X., Munshaw, S., Zhang, R., Marshall, D. J., Vander-grift,N.,Whitesides,J.F.,Lu,X.,Yu,J. S., Hwang, K. K., Gao, F., Markowitz, M., Heath, S. L., Bar, K. J., Goepfert, P. A., Montefiori, D. C., Shaw, G. C., Alam, S. M., Margolis, D. M., Denny,T.N.,Boyd,S.D.,Marshal,E., Egholm,M.,Simen,B.B.,Hanczaruk, B., Fire, A. Z., Voss, G., Kelsoe, G., Tomaras,G.D.,Moody,M.A.,Kepler, T. B.,and Haynes,B. F. (2011). Initial antibodies binding to HIV-1 gp41 in acutelyinfectedsubjectsarepolyreac-tive and highly mutated. J. Exp. Med. 208,2237-2249.
114. Lucas, K., and Roosen, P. (2010). Emer-gence,Analysis and EvolutionofStruc-tures. Berlin: SpringerVerlag.
115. Lynch, R. M., Rong, R., Boliar, S., Sethi, A., Li, B., Mulenga, J., Allen, S., Robinson, J. E., Gnanakaran, S., and Derdeyn, C. A. (2011). The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J. Virol. 85, 905-915.
116. Ma, B. J., Alam, S. M., Go, E. P., Lu, X., Desaire, H., Tomaras, G. D., Bowman, C., Sutherland, L. L., Scearce, R. M., Santra, S., Letvin, N. L., Kepler, T. B., Liao, H. X., and Haynes, B. F. (2011). Envelope deglycosylation enhances antigenic-ity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibod-ies. PLoS Pathog. 7, e1002200. doi: 10.1371/journal.ppat.1002200
117. Mahner, M., and Bunge, M. (1997). Foundations of Biophilosophy. Berlin: Springer.
118. Manivel, V., Bayiroglu, F., Siddiqui, Z., Salunke, D. M., Rao, and K. V. (2002). The primary antibody reper-toire represents a linked network of degenerate antigen specificities. J. Immunol. 169,888-897.
119. Manivel, V., Sahoo, N. C., Salunke, D. M., and Rao, K. V. (2000). Mat-uration of an antibody response is governed by modulations in flexi-bility of the antigen-combining site. Immunity 13, 611-620.
120. Marks, J. D. (1994). "Maturation of the immune response,"in Immunochem-istry, eds C. J. Van Oss and M. H. V. Van Regenmortel (New York: Marcel Dekker), 1039-1051.
121. Mascola, J. R. (1999). Herpes simplex virus vaccines -why don't antibod-ies protect? J. Am. Med. Assoc. 281, 379-80.
122. Mascola, J. R., Louder, M. K., VanCott, T. C., Sapan, C. V., Lambert, J. S., Muenz, L. R., Bunow, B., Birx, D. L., and Robb, M. L. (1997). Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperim-mune anti-HIV immunoglobulin combined with monoclonal antibod-ies 2F5 and 2G12. J. Virol. 71, 7198-7206.
123. Maynard-Smith, J. (2000). The concept of information in biology. Philos. Sci. 67,177-194.
124. Mayr, E. (1961). Cause and effect in biology. Science 134, 1501-1506.
125. Mazzocchi, F. (2008). Complexity in biology. EMBO Rep. 9,10-14.
126. McElrath, M. J., and Haynes, B. F. (2010). Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33, 542-554.
127. McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J. P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai,K.,O'Dell,S.,Patel,N.,Shahzad-ul-Hussan, S., Yang, Y., Zhang, B., Zhou, T., Zhu, J., Boyington, J. C., Chuang, G. Y., Diwanji, D., Georgiev, I., Kwon, Y. D., Lee, D., Louder, M. K., Moquin, S., Schmidt, S. D., Yang, Z. Y., Bonsignori, M., Crump, J. A., Kapiga, S. H., Sam, N. E., Haynes, B. F., Burton, D. R., Koff, W. C., Walker, L.M.,Phogat,S.,Wyatt,R.,Orwenyo, J., Wang, L. X., Arthos, J., Bewley, C. A., Mascola, J. R., Nabel, G. J., Schief, W. R., Ward, A. B., Wilson, I. A., and Kwong, P. D. (2011). Structure of HIV-1 gp120V1/V2 domain with broadly neutralizing antibody PG9. Nature 480,336-343.
128. Medawar, P. B., and Medawar, J. S.Williamson, C., Pinter, A., Morris, L., and CAPRISA 002 Study. (2011). Potent and broad neutralization of HIV-1 subtype C by plasma anti-bodies targeting a quaternary epitope including residues in the V2 loop. J. Virol. 85,3128-3141.
129. Moore, J. P., and Ho, D. D. (1993). Antibodies to discontinuous or con-formationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J. Virol. 67, 863-875.
130. Moran, M. J., Andris, J. S., Mat-sumato, Y., Capra, J. D., and Hersh, E. M. (1993). Variable region genes ofanti-HIVhumanmonoclonalanti-bodies: non-restricted use of the V gene repertoire and extensive somatic mutation. Mol. Immunol. 30, 1543-1551.
131. Morgan, C., Marthas, M., Miller, C., Duerr, A., Cheng-Mayer, C., Desrosiers, R., Flores, J., Haigwood, N., Hu, S. L., Johnson, R. P., Lif-son, J., Montefiori, D., Moore, J., Robert-Guroff, M., Robinson, H., Self, S., and Corey, L. (2008). The use of nonhuman primate models in HIVvaccinedevelopment.PLoSMed. 5, e173. doi: 10.1371/journal.pmed. 0050173
132. Morris, L., Chen, X., Alam, M., Tomaras, G., Zhang, R., Marshall, D. J., Chen, B., Parks, R., Foulger, A., Jaeger, F., Donathan, M., Bilska, M., Gray, E. S., Abdool Karim, S. S., Kepler, T. B., Whitesides, J., Monte-fiori, D., Moody, M. A., Liao, H. X., and Haynes, B. F. (2011). Isolation of a human anti-HIV gp41 mem-brane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One 6, e23532. doi: 10.1371/journal.pone.0023532
133. Moseri, A., Tantry, S., Sagi, Y., Arshava, B.,Naider,F.,andAnglister,J. (2010). An optimally constrainedV3 peptide is a better immunogen than its linear homolog or HIV-1 gp120. Virology 401,293-304.
134. Moss, L. (2003). What Genes Can't Do. Cambridge,MA: MIT Press.
135. Moudgil, K. D., Sercarz, E. E., and Gre-wal, I. S. (1998). Modulation of the immunogenicity of antigenic deter-minants by their flanking residues. Immunol. Today 19,217-220.
136. Mouquet, H., Klein, F., Scheid, J. F., Warncke, M., Pietzsch, J., Oliveira, T. Y., Velinzon, K., Seaman, M. S., and Nussenzweig, M. C. (2011). Mem-ory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PLoS ONE 6, e24078. doi: 10.1371/jour-nal.pone.0024078
137. Muster, T., Steindl, F., Purtscher, M., Trkola, A., Klima, A., Himmler, G., Rüker, F., and Katinger, H. (1993).Aconservedneutralizingepi-tope on gp41 of human immunod-eficiency virus type 1. J. Virol. 67, 6642-6647.
138. Nabel, G. J., Kwong, P. D., and Mascola, J. R. (2011). Progress in the ratio-naldesignof anAIDSvaccine. Philos. Trans. R. Soc. Lond. B Biol. Sci. 366, 2759-2765.
139. Nagel, T. (1998). "Reductionism and antireductionism," in The Limits of Reductionism in Biology. Novartis Foundation Symposium 213 (Chich-ester: Wiley),3-14.
140. Nakaya,H.I.,andPulendran,B.(2012). Systems vaccinology: its promise and challenge for HIV vaccine develop-ment. Curr. Opin. HIV AIDS 7, 24-31.
141. Nelson, J. D., Brunel, F. M., Jensen, R., Crooks, E. T., Cardoso, R. M., Wang, M., Hessell, A., Wil-son, I. A., Binley, J. M., Dawson, P. E., Burton, D. R., and Zwick, M. B. (2007). An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J. Virol. 81,4033-4043.
142. Neurath, A. R. (2008). "Antibody-mediated immunity to viruses," in DeskEncyclopediaofGeneralVirology, eds B. W. J. Mahy and M. H. V. Van Regenmortel (Amsterdam: Elsevier), 361-375.
143. Neurath, A. R., and Rubin, B. A. (1971). Viral Structural Compo-nents as Immunogens of Prophylactic Value. Monographs in Virology. Basel: Karger.
144. Newton-Smith, W. (1981). The Ratio-nality of Science. Boston: Routledge & Kegan Paul.
145. Nezlin, R. (1994). "Immunoglobulin structure and function," in Immuno-chemistry, eds C. J. van Oss and M. H. V. Van Regenmortel (New York: Marcel Dekker),pp 3-45.
146. Noble, D. (2006). The Music of Life: Biology Beyond the Genes.NewYork: Oxford University Press.
147. Noble, D. (2008). Genes and causation. Philos. Transact. A Math. Phys. Eng. Sci. 366,3001-3015.
148. Noble, D. (2012). A theory of bio-logical relativity: no privileged level of causation. Interface Focus 2, 55-64.
149. Obeid,O.E.,Partidos,C.D.,Howard,C. R., and Steward, M. W. (1995). Pro-tectionagainstmorbillivirus-induced encephalitis by immunization with a rationally designed synthetic peptide
150. vaccine containing B-and T-cell epitopes from the fusion pro-tein of measles virus. J.Virol. 69, 1420-1428.
151. Oberg, A. L., Kennedy, R. B., Li, P., Ovsyannikova, I. G., and Poland, G. A. (2011). Systems biology approaches to new vaccine develop-ment. Curr. Opin. Immunol. 23, 436-443.
152. Ofek, G., Guenaga, F. J., Schief, W. R., Skinner, J., Baker, D., Wyatt, R., and Kwong, P. D. (2010a). Elicitation of structure-specific antibodies by epi-tope scaffolds. Proc. Natl. Acad. Sci. U.S.A. 107,17880-19887.
153. Ofek, G., McKee, K., Yang, Y., Yang, Z. Y., Skinner, J., Guenaga, F. J., Wyatt, R., Zwick, M. B., Nabel, G. J., Mascola, J. R., and Kwong, P. D. (2010b). Relationship between anti-body 2F5 neutralization of HIV-1 andhydrophobicityof itsheavychain third complementarity-determining region. J. Virol. 84, 2955-2962.
154. Ofek, G., Tang, M., Sambor, A., Katinger, H., Mascola, J. R., Wyatt, R., and Kwong, P. D. (2004). Struc-ture and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78, 10724-10737.
155. Okulicz, J. F. (2012). Elite controllers andlong-termnonprogressors:mod-els for HIV vaccine development? J. AIDS Clin. Res. S8,005.
156. O'Malley, M. A., and Dupré, J. (2005). Fundamental issues in systems biol-ogy. Bioessays 27, 1270-1276.
157. Overbaugh, J., and Morris, L. (2012). The antibody response against HIV-1. Cold Spring Harb. Perspect. Med. 2, a007039.
158. Oyama, S. (2009). The Ontogeny of Information,2nd Edn. Durham,NC: Duke University Press.
159. Oyama, S., Griffiths P. E., and Gray, R. D .(eds)(2001).Cycles of Contingency: Developmental Systems and Evolution. Cambridge, MA: The MIT Press.
160. Pancera, M., McLellan, J. S., Wu, X., Zhu, J., Changela, A., Schmidt, S. D., Yang, Y., Zhou, T., Phogat, S., Mascola, J. R., and Kwong, P. D. (2010). Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J. Virol. 84, 8098-8110.
161. Pantophlet,R.(2010).Antibodyepitope exposure and neutralization of HIV-1. Curr. Pharm. Des. 16, 3729-3743.
162. Pantophlet, R., and Burton, D. R. (2003). Immunofocusing: antigen engineering to promote the induc-tion of HIV-neutralizing antibodies. Trends Mol. Med. 9,468-473.
163. Pantophlet, R., Wilson, I. A., and Burton, D. R. (2003a). Hyperglyco-sylated mutants of human immun-odeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J. Virol. 77, 5889-5901.
164. Pantophlet, R., Ollmann Saphire, E., Poignard, P., Parren, P. W., Wilson, I. A.,and Burton,D. R. (2003b). Fine mapping of the interaction of neu-tralizing and nonneutralizing mono-clonal antibodies with the CD4 bind-ing site of human immunodeficiency virus type 1 gp120. J. Virol. 77, 642-658.
165. Parnes, O. (2004). From interception to incorporation: degeneracy and promiscuous recognition as precur-sors of a paradigm shift in immunol-ogy. Mol. Immunol. 40, 985-991.
166. Pejchal, R., and Wilson, I. A. (2010). Structure-based vaccine design in HIV: blind men and the elephant? Curr. Pharm. Des. 16, 3744-3753.
167. Pejchal, R., Walker, L. M., Stanfield, R. L., Phogat, S. K., Koff, W. C., Poignard, P., Burton, D. R., and Wilson, I. A. (2010). Structure and function of broadly reactive anti-body PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1.Proc.Natl.Acad.Sci.U.S.A. 107, 11483-11488.
168. Pulendran, B., Li, S., and Nakaya, H. I. (2010). Systems vaccinology. Immunity 33,516-529.
169. Psillos, S. (2002). Causation and Expla-nation. Chesham and Montreal:Acu-men and McGill-Queen's University Press.
170. Querec, T. D., Akondy, R. S., Lee, E. K., Cao, W., Nakaya, H. I., Teuwen, D., Pirani, A., Gernert, K., Deng, J., Marzolf, B., Kennedy, K., Wu, H., Bennouna, S., Oluoch, H., Miller, J., Vencio, R. Z., Mulligan, M., Aderem, A., Ahmed, R., and Pulendran, B. (2009). Systems biology approach predicts immunogenicity of the yel-low fever vaccine in humans. Nat. Immunol. 10, 116-125.
171. Rappuoli, R. (2001). Reverse vacci-nology, a genome-based approach to vaccine development. Vaccine 19, 2688-2691.
172. Rappuoli, R., and Bagnoli, F., eds. (2011). Vaccine Design: Innovative Approaches and Novel Strategies.Nor-folk, UK: Caister Academic Press.
173. Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., Benenson, M., Gurunathan, S., Tartaglia, J., McNeil, J. G., Fran-cis, D. P., Stablein, D., Birx, D. L., Chunsuttiwat, S., Khamboon-ruang, C., Thongcharoen, P., Robb, M. L., Michael, N. L., Kunasol, P., Kim, J. H., and MOPH-TAVEG Investigators. (2009). Vaccination withALVACandAIDSVAXtoprevent HIV-1 infection in Thailand. N. Engl. J. Med. 361,2209-2220.
174. Richards, F. F., Konigsberg, W. H., Rosenstein, R. W., and Varga, J. M. (1975). On the specificity of antibod-ies. Science 187,130-137.
175. Robinson, J. E., Franco, K., Elliott, D. H., Maher, M. J., Reyna, A., Montefiori, D. C., Zolla-Pazner, S., Gorny, M. K., Kraft, Z., and Stamatatos, L. (2010). Qua-ternary epitope specificities of anti-HIV-1 neutralizing antibodies gen-erated in rhesus macaques infected by the simian/human immunodefi-ciency virus SHIVSF162P4. J. Virol. 84,3443-3453.
176. Rolland, M., and Gilbert, P. (2012). EvaluatingimmunecorrelatesinHIV type 1 vaccine efficacy trials: what RV144 may provide. AIDS Res. Hum. Retroviruses 28,400-404.
177. Rose, S. (1998). "What is wrong with reductionist explanations of behav-ior?," in The Limits of Reductionism in Biology. Novartis Foundation Sym-posium No 213, eds G. Bock and J. Goode (Chichester: Wiley),176.
178. Rosen, R. (1991). Life Itself: A compre-hensive Inquiry into the Nature, Origin and Fabrication of Life.NewYork: Columbia University Press.
179. Rosenberg, A. (1994). Instrumental Biology or the Disunity of Science. Chicago: Chicago University Press.
180. Ruse, M. (2002). Darwin and Design: Does Evolution Have a Purpose? Cambridge, MA: Harvard University Press.
181. Sattentau, Q. J., and McMichael, A. J. (2010). New templates for HIV-1 antibody-based vaccine design. F1000 Biol. Rep. 2,60.
182. Scanlan, C. N., Pantophlet, R., Wormald,M.R.,OllmannSaphire,E., Stanfield, R., Wilson, I. A., Katinger, H., Dwek, R. A., Rudd, P. M., and Burton, D. R. (2002). The broadly neutralizing anti-human immunod-eficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1→2 mannose residues on the outer face of gp120. J. Virol. 76,7306-7321.
183. Scheid, J. F., Mouquet, H., Feldhahn, N., Seaman, M. S.,Velinzon, K., Piet-zsch, J., Ott, R. G., Anthony, R. M., Zebroski, H., Hurley, A., Phogat, A., Chakrabarti, B., Li, Y., Con-nors, M., Pereyra, F., Walker, B. D., Wardemann, H., Ho, D., Wyatt, R. T., Mascola, J. R., Ravetch, J. V., and Nussenzweig, M. C. (2009). Broad diversity of neutralizing anti-bodies isolated from memory B cells in HIV-infected individuals. Nature 458,636-640.
184. Scheid, J. F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T. Y., Pietzsch, J., Fenyo, D., Abadir, A., Velinzon, K., Hurley, A., Myung, S., Boulad,F.,Poignard,P.,Burton,D.R., Pereyra, F., Ho, D. D., Walker, B. D., Seaman,M. S.,Bjorkman,P. J.,Chait, B.T.,andNussenzweig,M.C.(2011). Sequence and structural convergence of broad and potent HIV antibodies thatmimicCD4binding.Science 333, 1633-1637.
185. Scherer,E. M.,Leaman,D. P.,Zwick,M. B., McMichael, A. J., and Burton, D. R. (2010). Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recogni-tionthroughmembraneinteractions. Proc. Natl. Acad. Sci. U.S.A. 107, 1529-1534.
186. Shedlock,D.J.,Silvestri,G.,andWeiner, D.B.(2009).Monkeyingaroundwith HIVvaccines:usingrhesusmacaques to define "gatekeepers" for clinical trials. Nat. Rev. Immunol. 9,717-728.
187. Schildbach, J. F., Near, R. I., Brucco-leri, R. E., Haber, E., Jeffrey, P. D., Novotny, J., Sheriff, S., and Mar-golies, M. N. (1993). Modulation of antibody affinity by a non-contact residue. Protein Sci. 2, 206-214.
188. Schroer, J. A., Bender, T., Feldmann, T., and Kim, K. J. (1983). Map-pingepitopesontheinsulinmolecule using monoclonal antibodies. Eur. J. Immunol. 13, 693-700.
189. Shapiro,J.A.(2009). Revisitingthecen-tral dogma in the 21st century. Ann. N.Y. Acad. Sci. 1178, 6-28.
190. Simek, M. D., Rida, W., Priddy, F. H., Pung, P., Carrow, E., Laufer, D. S., Lehrman, J. K., Boaz, M., Tarragona-Fiol,T.,Miiro,G.,Birungi, J., Pozniak, A., McPhee, D. A., Manigart, O., Karita, E., Inwoley, A., Jaoko, W., Dehovitz, J., Bekker, L. G., Pitisuttithum, P., Paris, R., Walker, L. M., Poignard, P., Wrin, T., Fast, P. E., Burton, D. R., and Koff, W. C. (2009). Human immun-odeficiency virus type 1 elite neu-tralizers: individuals with broad and potentneutralizingactivityidentified by using a high-throughput neutral-ization assay together with an analyt-ical selection algorithm. J. Virol. 83, 7337-7348.
191. Sperling,R.,Francus,T.,andSiskind,G. W. (1983). Degeneracy of antibody specificity. J. Immunol. 131,882-885.
192. Stamatatos, L., Morris, L., Burton, D. R., and Mascola, J. R. (2009). Neutralizing antibodies generated duringnaturalHIV-1infection:good newsforanHIV-1vaccine?Nat.Med. 15,866-870.
193. Stanfield, R. L., Gorny, M. K.,Williams, C., Zolla-Pazner, S., and Wilson, I. A. (2004). Structural rationale for the broad neutralization of HIV-1 byhumanmonoclonalantibody447-52D. Structure 12,193-204.
194. Sundberg, E. J., and Mariuzza, R. A. (2002). Molecular recognition in antibody-antigen complexes. Adv. Protein Chem. 61,119-160.
195. Talmage, D. W. (1959). Immunologi-cal specificity, unique combinations of selected natural globulins provide analternativetotheclassicalconcept. Science 129,1643-1648.
196. Thomas, C. (2009). Roadblocks in HIV research:fivequestions.Nat.Med.15, 855-859.
197. Tian, Y., Ramesh, C. V., Ma, X., Naqvi, S., Patel, T., Cenizal, T., Tiscione, M., Diaz, K., Crea, T., Arnold, E., Arnold,G.F.,andTaylor,J.W.(2002). Structure-affinityrelationshipsinthe gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and back-bone modifications and conforma-tional constraints. J. Pept. Res. 59, 264-276.
198. Tomaras, G. D., Binley, J. M., Gray, E. S., Crooks, E. T., Osawa, K., Moore, P. L., Tumba, N., Tong, T., Shen, X., Yates, N. L., Decker, J., Wibmer, C. K., Gao, F.,Alam, S. M., Easterbrook, P., Abdool Karim, S., Kamanga, G., Crump,J.A.,Cohen,M.,Shaw,G.M., Mascola, J. R., Haynes, B. F., Monte-fiori, D. C., and Morris, L. (2011). Polyclonal B cell responses to con-served neutralization epitopes in a subset of HIV-1-infected individuals. J. Virol. 85,11502-11519.
199. Tropsha,A., Kizler, J. S., and Chaiken, I. M.(1992).Makingsenseofantisense: a review of experimental data and developing ideas on sense-antisense recognition. J. Mol. Recognit. 5, 43-54.
200. VanCott, T. C., Bethke, F. R., Burke, D. S., Redfield, R. R., and Birx, D. L. (1995). Lack of induction of anti-bodiesspecificforconserved,discon-tinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vac-cines. J. Immunol. 155, 4100-4110.
201. Van Bubnoff, A. (2010). Vaccines to Antibodies: Grow Up.IAVIReport, July-August 2010.
202. Van Regenmortel, M. H. V. (1998a). From absolute to exquisite speci-ficity. Reflections on the fuzzy nature of species, specificity and antigenic sites. J. Immunol. Methods 216, 37-48.
203. Van Regenmortel, M. H. V. (1998b). Mimotopes, continuous paratopes and hydropathic complementar-ity: novel approximations in the description of immunological speci-ficity. J. Disper. Sci. Technol. 8, 140-144.
204. Van Regenmortel, M. H. V. (1999). Molecular design versus empirical discovery in peptide-based vaccines. Coming to terms with fuzzy recog-nition sites and ill-defined structure function relationships in immunol-ogy. Vaccine 18,216-221.
205. Van Regenmortel, M. H. V. (2002a). Reductionism and the search for structure-function relationships in antibody molecules. J. Mol. Recognit. 15,240-247.
206. Van Regenmortel, M. H. V. (2002b). "Pitfalls of reductionism in immunology,"in Promises and Limits of Reductionism in the Biomedical Sciences,eds M. H.V.Van Regenmor-tel and D. L. Hull (Chichester: John Wiley).
207. VanRegenmortel,M.H.V.(2004a).Bio-logical complexity emerges from the ashes of genetic reductionism. J. Mol. Recognit. 17, 145-148.
208. Van Regenmortel, M. H. V. (2004b). Reductionism and complexity in molecular biology. Scientists now have the tools to unravel biological complexity and overcome the limita-tions of reductionism. EMBO Rep. 5, 1016-1020.
209. Van Regenmortel, M. H. V. (2006). Immunoinformatics may lead to a reappraisal of the nature of B cell epitopes and of the feasibility of synthetic peptide vaccines. J. Mol. Recognit. 19, 183-187.
210. Van Regenmortel, M. H. V. (2007). The rational design of biological com-plexity: a deceptive metaphor. Pro-teomics 7,965-975.
211. Van Regenmortel, M. H. V. (2009a). Synthetic peptide vaccines and the search for neutralization B cell epi-topes. Open Vaccine J. 2,33-44.
212. Van Regenmortel, M. H. V. (2009b). "What is a B cell epitope?," in Epitope Mapping Protocols,eds U. Reineke and M. Schotkowski (Springer: Humana Press) 3-20.
213. Van Regenmortel, M. H. V. (2011a). Limitations to the structure-based design of HIV-1 vaccine immunogens. J. Mol. Recognit. 24, 741-753.
214. Van Regenmortel, M. H. V. (2011b). Two meanings of reverse vaccinology and the empirical nature of vaccine science. Vaccine 29, 7875.
215. Van Regenmortel, M. H. V. (2012). Requirements for empirical immunogenicity trials, rather thanstructure-based design, for develop-ing an effective HIV vaccine. Arch. Virol. 157, 1-20.
216. Van Regenmortel, M. H. V., and Hull, D. L. (2002). Promises and Limits of Reductionism in the Biomedical Sci-ences. Chichester: John Wiley.
217. Van Regenmortel, M. H. V., and Muller, S. (1999). Synthetic Peptides as Anti-gens. Amsterdam: Elsevier.
218. Van Regenmortel, M. H. V., and Neu-rath, A. R. (1985). Immunochemistry of Viruses. Amsterdam: Elsevier.
219. Verkoczy, L., Kelsoe, G., Moody, M. A., and Haynes, B. F. (2011). Role of immunemechanismsininduction of HIV-1 broadly neutralizing anti-bodies. Curr. Opin. Immunol. 23, 383-390.
220. Virgin, H. W., and Walker, B. D. (2010). Immunology and the elusive AIDS vaccine. Nature 464,224-231.
221. Wagner,A.(1999).Causalityincomplex systems. Biol. Philos. 14,83-101.
222. Walker,L. M.,and Burton,D. R. (2010). Rational antibody-based HIV-1 vac-cine design: current approaches and future directions. Curr. Opin. Immunol. 22, 358-366.
223. Walker, L. M., Phogat, S. K., Chan-Hui, P. Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham,J.L.,Lehrman,J.K.,Priddy, F. H., Olsen, O. A., Frey, S. M., Ham-mond, P. W.; Protocol G Principal Investigators,Kaminsky,S.,Zamb,T., Moyle, M., Koff, W. C., Poignard, P., and Burton, D. R. (2009). Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289
224. Walker, L. M., Simek, M. D., Priddy, F., Gach, J. S., Wagner, D., Zwick, M. B., Phogat, S. K., Poignard, P., and Burton,D. R. (2010).A limited num-ber of antibody specificities mediate broad and potent serum neutraliza-tion in selected HIV-1 infected indi-viduals. PLoS Pathog. 6, e1001028. doi: 10.1371/journal.ppat.1001028
225. Wilkins, A. S. (2001). Why the philos-ophy of science actually does matter. Bioessays 23, 561-562.
226. Wilson,I.A.,andStanfield,R.L.(1994). Antibody-antigen interactions: new structures and new conformational changes. Curr. Opin. Struct. Biol. 4, 857-867.
227. Wlodawer, A. (2002). Rational approach to AIDS drug design through structural biology. Annu. Rev. Med. 53, 595-514.
228. Woodward, J. (2003). Making Things Happen: A Theory of Causal Expla-nation. Oxford: Oxford University Press.
229. Wu, X., Changela, A., O'Dell, S., Schmidt, S. D., Pancera, M., Yang, Y., Zhang, B., Gorny, M. K., Phogat, S., Robinson, J. E., Stamatatos, L., Zolla-Pazner, S., Kwong, P. D., and Mascola, J. R. (2011a). Immuno-types of a quaternary site of HIV-1 vulnerability and their recogni-tion by antibodies. J. Virol. 85, 4578-4585.
230. Wu, X., Yang, Z. Y., Li, Y., Hogerkorp, C. M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., Longo, N. S., McKee, K., O'Dell, S.,Louder,M.K.,Wycuff,D. L.,Feng, Y., Nason, M., Doria-Rose, N., Con-nors, M., Kwong, P. D., Roederer, M., Wyatt, R. T., Nabel, G. J., and Mas-cola, J. R. (2010). Rational design of envelope identifiesbroadlyneutraliz-ing human monoclonal antibodies to HIV-1. Science 329,856-861.
231. Wu, X., Zhou, T., Zhu, J., Zhang, B., Georgiev, I., Wang, C., Chen, X., Longo, N. S., Louder, M., McKee, K., O'Dell, S., Perfetto, S., Schmidt, S. D., Shi, W., Wu, L., Yang, Y., Yang, Z. Y., Yang, Z., Zhang, Z., Bonsignori, M., Crump, J. A., Kapiga, S. H., Sam, N. E., Haynes, B. F., Simek, M., Bur-ton,D.R.,Koff,W.C.,Doria-Rose,N. A., Connors, M., NISC Comparative Sequencing Program, Mullikin, J. C., Nabel, G. J., Roederer, M., Shapiro, L., Kwong, P. D., and Mascola, J. R. (2011b). Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Sci-ence 333,1593-1602.
232. Wucherpfennig, K. W., Allen, P. M., Celada, F., Cohen, I. R., De Boer, R., Garcia, K. C., Goldstein, B., Greenspan, R., Hafler, D., Hodgkin, P., Huseby, E. S., Krakauer, D. C., Nemazee, D., Perelson, A. S., Pinilla, C., Strong, R. K., and Sercarz, E. E. (2007). Poly-specificity of T cell and B cell receptor recognition. Semin. Immunol. 19, 216-224.
233. Xiao, X., Chen, W., Feng, Y., Zhu, Z., Prabakaran, P., Wang, Y., Zhang, M. Y., Longo, N. S., and Dimitrov, D. S. (2009). Germline-like predeces-sors of broadly neutralizing antibod-ies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem.Biophys.Res.Commun.390, 404-409.
234. Yin, J., Beuscher, A. E. 4th, Andryski, S. E., Stevens, R. C., and Schultz, P. G. (2003). Structural plasticity and the evolution of antibody affin-ity and specificity. J. Mol. Biol. 330, 651-656.
235. Zajac, A. J., and Harrington, L. E. (2008). "Cell-mediated immunity to viruses,"inDeskEncyclo.ofGen.Virol. eds B. W. J. Mahy and M. H. V. Van Regenmortel (Amsterdam: Elsevier), 354-361.
236. Zhou, T., Georgiev, I., Wu, X., Yang, Z. Y., Dai, K., Finzi, A., Kwon, Y. D., Scheid, J. F., Shi, W., Xu, L., Yang, Y., Zhu, J., Nussenzweig, M. C., Sodroski, J., Shapiro, L., Nabel, G. J., Mascola, J. R., and Kwong, P. D. (2010). Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-817.
237. Zhou, T., Xu, L., Dey, B., Hessell, A. J., Van Ryk, D., Xiang, S. H., Yang, X., Zhang, M. Y., Zwick, M. B., Arthos, J., Burton, D. R., Dimitrov, D. S., Sodroski, J., Wyatt, R., Nabel, G. J., and Kwong, P. D. (2007). Structural definition of a conserved neutraliza-tion epitope on HIV-1 gp120. Nature 445,732-737.
238. Zhu, Z., Bossart, K. N., Bishop, K. A., Crameri, G., Dimitrov, A. S., McEachern, J. A., Feng, Y., Middle-ton, D., Wang, L. F., Broder, C. C., and Dimitrov, D. S. (2008). Excep-tionallypotentcross-reactiveneutral-ization of Nipah and Hendra viruses by a human monoclonal antibody. J. Infect. Dis. 197,845-853.
239. Zhu, Z., Qin, H. R., Chen, W., Zhao, Q., Shen, X., Schutte, R., Wang, Y., Ofek, G., Streaker, E., Prabakaran, P., Fouda, G. G., Liao, H. X., Owens, J., Louder, M., Yang, Y., Klaric, K. A., Moody, M. A., Mascola, J. R., Scott, J. K., Kwong, P. D., Montefiori, D., Haynes, B. F., Tomaras, G. D., and Dimitrov,D.S.(2011).Cross-reactive HIV-1-neutralizing human mono-clonal antibodies identified from a patient with 2F5-like antibodies. J. Virol. 85,11401-11408.
240. Zolla-Pazner,S. (2004). Identifying epi-topesof HIV-1thatinduceprotective antibodies. Nat. Rev. Immunol. 4, 199-210.
241. Zolla-Pazner,S.,andCardozo,T.(2010). Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat. Rev. Immunol. 10,527-535.
242. Zolla-Pazner, S., Kong, X. P., Jiang, X., Cardozo, T., Nádas, A., Cohen, S., Totrov, M., Seaman, M. S., Wang, S., and Lu, S. (2011). Cross-clade HIV-1 neutralizing antibod-ies induced with V3-scaffold pro-tein immunogens following priming with gp120 DNA. J. Virol. 85, 9887-9898.
243. Zwick, M. B. (2005). The membrane-proximal external region of HIV-1 gp41: a vaccine target worth explor-ing. AIDS 19,1725-1737.
244. Zwick, M. B., Parren, P. W., Saphire, E. O., Church, S., Wang, M., Scott, J. K., Dawson, P. E., Wilson, I. A., and Burton, D. R. (2003). Molecular features of the broadly neutralizing immunoglobulinG1b12requiredfor recognition of human immunodefi-ciency virus type 1 gp120. J.Virol. 77, 5863-5876.
245. Zwick, M. B., Wang, M., Poignard, P., Stiegler, G., Katinger, H., Burton, D. R.,and Parren,P.W. (2001). Neutral-ization synergy of human immunod-eficiency virus type 1 primary iso-lates by cocktails of broadly neu-tralizing antibodies. J. Virol. 75, 12198-12208.